



Average FY Product Sales Consensus

€m	2019a	2020e	2021e	2022e	2023e	2024e	2025e	Peak Sales	NPV
Core Products									
Cimzia	1,712	1,800	1,888	1,946	1,941	1,776	1,522		5,080
Vimpat	1,322	1,449	1,549	1,382	867	682	556		2,580
Keppra	770	764	715	647	592	546	499		2,210
Briviact	221	295	364	431	492	545	583	627	1,761
Neupro	319	301	261	217	185	159	136		494
Potential new product launches (global sales, non-risk adj.)									
Evenity		399	582	731	865	989	1,084	1,297	2,082
Nayzilam		23	45	66	87	104	113	141	334
Bimekizumab		0	98	355	672	1,010	1,372	2,323	5,324
Zilucoplan		0	0	39	153	315	490	1,116	2,235
Rozanolixizumab (Rozimab)		0	0	16	88	198	367	1,058	1,899
Dapimab		0	7	16	34	60	109		
Staccato alprazolam		0	0	1	3	42	120		
UCB0107 (Anti-Tau)		0	0	0	13	78	138		

Median FY Product Sales Consensus

€m	2019a	2020e	2021e	2022e	2023e	2024e	2025e	Peak Sales	NPV
Core Products									
Cimzia	1,712	1,804	1,906	1,973	1,985	1,794	1,516		5,035
Vimpat	1,322	1,452	1,540	1,401	909	684	539		2,564
Keppra	770	761	714	641	592	539	487		2,102
Briviact	221	294	360	423	482	537	584	599	1,709
Neupro	319	305	256	214	188	162	135		519
Potential new product launches (global sales, non-risk adj.)									
Evenity		403	580	698	837	1,003	1,091	1,300	1,932
Nayzilam		25	48	68	89	107	113	150	284
Bimekizumab		0	84	354	700	1,044	1,329	2,303	5,094
Zilucoplan		0	0	0	140	299	447	1,095	1,957
Rozanolixizumab (Rozimab)		0	0	0	83	170	353	985	1,708
Dapimab		0	0	0	0	0	63		
Staccato alprazolam		0	0	0	0	30	88		
UCB0107 (Anti-Tau)		0	0	0	0	82	129		

Based on the estimates of 17 brokers
Last updated: 26/11/20